Posted by Michael Wonder on 11 Dec 2023
ICER identifies most significant 2022 US drug price hikes unsupported by new clinical evidence
11 December 2023 - Of 10 high expenditure drugs that had substantial 2022 net price increases, eight were not supported by new clinical evidence; these increases accounted for $1.27 billion in additional costs over one year.
The ICER today published its latest report on unsupported price increases of prescription drugs in the United States.
